OBJECTIVES: Options for the treatment of well-differentiated neuroendocrine tumors (NETs) are limited. We evaluated the efficacy of capecitabine and temozolomide combination in patients from Jordan. METHODS: A retrospective review was conducted of 21 patients with metastatic well-differentiated NETs who failed somatostatin analogues and chemotherapy. Patients received capecitabine and temozolomide regimen every 28 days, and evaluation was done every 2 cycles. RESULTS: Twelve patients (57%) achieved partial response, and 5 (23%) achieved stable disease. Median progression-free survival was 16.5 months (range, 14.8-18 months). Of the 7 carcinoid tumors, 2 had partial response, and 2 had stable disease. There were no grade 4 toxicities or treatment-related deaths. CONCLUSIONS: Capecitabine and temozolomide regimen is an effective and well-tolerated salvage option for well-differentiated NETs.
OBJECTIVES: Options for the treatment of well-differentiated neuroendocrine tumors (NETs) are limited. We evaluated the efficacy of capecitabine and temozolomide combination in patients from Jordan. METHODS: A retrospective review was conducted of 21 patients with metastatic well-differentiated NETs who failed somatostatin analogues and chemotherapy. Patients received capecitabine and temozolomide regimen every 28 days, and evaluation was done every 2 cycles. RESULTS: Twelve patients (57%) achieved partial response, and 5 (23%) achieved stable disease. Median progression-free survival was 16.5 months (range, 14.8-18 months). Of the 7 carcinoid tumors, 2 had partial response, and 2 had stable disease. There were no grade 4 toxicities or treatment-related deaths. CONCLUSIONS:Capecitabine and temozolomide regimen is an effective and well-tolerated salvage option for well-differentiated NETs.
Authors: Louis de Mestier; Thomas Walter; Camille Evrard; Paul de Boissieu; Olivia Hentic; Jérôme Cros; David Tougeron; Catherine Lombard-Bohas; Vinciane Rebours; Pascal Hammel; Philippe Ruszniewski Journal: Neuroendocrinology Date: 2019-05-10 Impact factor: 4.914
Authors: Alex J Liu; Benjamin E Ueberroth; Patrick W McGarrah; Skye A Buckner Petty; Ayse Tuba Kendi; Jason Starr; Timothy J Hobday; Thorvardur R Halfdanarson; Mohamad Bassam Sonbol Journal: Oncologist Date: 2021-02-08
Authors: Paula Espinosa-Olarte; Anna La Salvia; Maria C Riesco-Martinez; Beatriz Anton-Pascual; Rocio Garcia-Carbonero Journal: Rev Endocr Metab Disord Date: 2021-04-11 Impact factor: 9.306